CA3049640A1 - Compounds and methods for trans-membrane delivery of molecules - Google Patents

Compounds and methods for trans-membrane delivery of molecules Download PDF

Info

Publication number
CA3049640A1
CA3049640A1 CA3049640A CA3049640A CA3049640A1 CA 3049640 A1 CA3049640 A1 CA 3049640A1 CA 3049640 A CA3049640 A CA 3049640A CA 3049640 A CA3049640 A CA 3049640A CA 3049640 A1 CA3049640 A1 CA 3049640A1
Authority
CA
Canada
Prior art keywords
set forth
formulae
solvates
hydrates
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3049640A
Other languages
English (en)
French (fr)
Inventor
Ilan Ziv
Joseph Dubrovsky
Hagit Grimberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aposense Ltd
Original Assignee
Aposense Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aposense Ltd filed Critical Aposense Ltd
Publication of CA3049640A1 publication Critical patent/CA3049640A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3049640A 2017-01-09 2018-01-09 Compounds and methods for trans-membrane delivery of molecules Pending CA3049640A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443822P 2017-01-09 2017-01-09
US62/443,822 2017-01-09
PCT/IL2018/050031 WO2018127927A1 (en) 2017-01-09 2018-01-09 Compounds and methods for trans-membrane delivery of molecules

Publications (1)

Publication Number Publication Date
CA3049640A1 true CA3049640A1 (en) 2018-07-12

Family

ID=62789169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049640A Pending CA3049640A1 (en) 2017-01-09 2018-01-09 Compounds and methods for trans-membrane delivery of molecules

Country Status (10)

Country Link
US (1) US11230710B2 (https=)
EP (1) EP3565603B1 (https=)
JP (1) JP7348064B2 (https=)
KR (1) KR20190104392A (https=)
CN (1) CN110402152B (https=)
AU (1) AU2018205898B2 (https=)
CA (1) CA3049640A1 (https=)
EA (1) EA201991661A1 (https=)
IL (1) IL267919B2 (https=)
WO (1) WO2018127927A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
WO2018127927A1 (en) 2017-01-09 2018-07-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10195286B2 (en) * 2017-07-04 2019-02-05 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2019130319A1 (en) * 2018-01-01 2019-07-04 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2020044349A1 (en) * 2018-08-30 2020-03-05 Aposense Ltd. Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules
WO2023022055A1 (ja) * 2021-08-17 2023-02-23 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
WO2025096244A1 (en) * 2023-10-30 2025-05-08 Olfera Corporation Olfactory delivery scaffolds and methods for making and using same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
WO1998050041A1 (en) 1997-05-06 1998-11-12 Imarx Pharmaceutical Corp. Novel prodrugs comprising fluorinated amphiphiles
FR2846969A1 (fr) 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
SE527131C2 (sv) 2004-02-13 2005-12-27 Innoventus Project Ab Steroider för cancerbehandling
WO2006006156A2 (en) 2004-07-08 2006-01-19 Nst Neurosurvival Technologies Ltd Compounds/methods for detection of medical disorders
KR20070053214A (ko) * 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
NZ554176A (en) 2004-10-01 2010-04-30 Prometic Biosciences Inc Medium-chain length fatty alcohols as stimulators of hematopoiesis
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
AU2007299705B2 (en) 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2972694C (en) 2008-05-13 2020-02-11 University Of Washington Diblock copolymers and polynucleotide complexes thereof for delivery into cells
WO2009155335A2 (en) 2008-06-19 2009-12-23 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US20120035362A1 (en) 2010-08-03 2012-02-09 Berry And Associates, Inc. Phosphoramidite derivatives of folic acid
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
CA2876860A1 (en) 2012-05-30 2013-12-05 Baylor College Of Medicine Supercoiled minivectors as a tool for dna repair, alteration and replacement
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
WO2014127052A1 (en) 2013-02-13 2014-08-21 Zondlo Neal Perfluoro-tert-butyl hydroxyproline
AU2014348212C1 (en) 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9889202B2 (en) 2014-03-28 2018-02-13 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
CA2944141C (en) * 2014-03-28 2023-03-28 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US20160016855A1 (en) * 2014-07-21 2016-01-21 Benxin Wu Fabrication of carbon nanotube-nonoxide structural ceramic nanocomposites through laser sintering
WO2018127927A1 (en) 2017-01-09 2018-07-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10195286B2 (en) 2017-07-04 2019-02-05 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules

Also Published As

Publication number Publication date
EP3565603B1 (en) 2022-12-07
KR20190104392A (ko) 2019-09-09
IL267919A (en) 2019-09-26
AU2018205898B2 (en) 2020-12-10
IL267919B2 (en) 2024-03-01
AU2018205898A1 (en) 2019-08-22
WO2018127927A1 (en) 2018-07-12
US20200392490A1 (en) 2020-12-17
US11230710B2 (en) 2022-01-25
EA201991661A1 (ru) 2019-12-30
EP3565603A4 (en) 2020-09-09
CN110402152B (zh) 2024-03-19
JP2020514299A (ja) 2020-05-21
JP7348064B2 (ja) 2023-09-20
EP3565603A1 (en) 2019-11-13
IL267919B1 (en) 2023-11-01
CN110402152A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
US11230710B2 (en) Compounds and methods for trans-membrane delivery of molecules
US9687556B2 (en) Compounds and methods for trans-membrane delivery of molecules
AU2016308066B2 (en) Compounds and methods for trans-membrane delivery of molecules
US10195286B2 (en) Compounds and methods for trans-membrane delivery of molecules
US12337036B2 (en) Compounds and methods for trans-membrane delivery of molecules
JP7854977B2 (ja) 分子の膜貫通送達のための化合物および方法
US20190125884A1 (en) Compounds and methods for trans-membrane delivery of molecules
HK40034155A (en) Compounds and methods for trans-membrane delivery of molecules
HK40027749A (en) Compounds and methods for trans-membrane delivery of molecules

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241018

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250113

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251230